LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
Rhea-AI Summary
LIXTE Biotechnology (Nasdaq:LIXT) filed its Form 10-Q for the quarter ended March 31, 2026, and reported progress across its oncology programs.
The company is expanding its ovarian cancer trial of lead compound LB-100 after a study confirmed a favorable safety profile in combination with GSK’s dostarlimab, and presented favorable preliminary clinical results at the 2026 Society of Gynecological Cancer Conference.
LIXTE also advanced integration and strategic initiatives at its recently acquired subsidiary Liora Technologies Europe, supporting growth of the LiGHT System proton therapy platform, while continuing proof-of-concept trials in multiple cancers and maintaining a comprehensive patent portfolio.
AI-generated analysis. Not financial advice.
Positive
- Expanded ovarian cancer trial of LB-100 after favorable safety study with dostarlimab
- Presented favorable preliminary LB-100 plus dostarlimab clinical results in ovarian clear cell carcinoma
- Advanced integration and growth initiatives at Liora Technologies Europe during Q1 2026
- Continued expansion of Liora’s LiGHT System proton therapy platform in Europe
- LB-100 shown well-tolerated at doses associated with anti-cancer activity
- Proof-of-concept clinical trials ongoing in three cancer indications, supported by patent portfolio
Negative
- None.
News Market Reaction – LIXT
On the day this news was published, LIXT gained 2.38%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $66.45M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
LIXT slipped 1.38% while close peers showed mixed action: two movers up and two down in momentum scans, with individual moves near ±4%. This points more to stock-specific trading than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Clinical trial update | Positive | -3.9% | Phase trial interim results for LB-100 plus dostarlimab in ovarian cancer. |
| Mar 31 | Annual report & financing | Positive | -1.9% | 2025 Form 10-K with capital raises, expanded trials, and Liora acquisition. |
| Feb 18 | Subsidiary leadership change | Positive | +1.3% | Appointment of Sidney Braun as CEO of Liora Technologies Europe. |
| Jan 21 | Health summit sponsorship | Positive | +4.0% | Sponsorship of Good Health Summit focused on health equity initiatives. |
| Jan 20 | Conference participation | Positive | -8.4% | Participation and investor meetings at DealFlow Discovery Conference. |
Recent history shows mixed reactions to generally positive news, with three notable selloffs and two rallies following operational and clinical updates.
Over the past six months, LIXTE has reported several milestones, including favorable ovarian cancer data on Apr 13, 2026, a detailed 2025 Form 10-K with capital raises and the Liora acquisition on Mar 31, 2026, and leadership appointments at Liora on Feb 18, 2026. The company also sponsored the Good Health Summit on Feb 19, 2026 and attended the DealFlow Discovery Conference in late January. Despite mostly constructive operational news, share reactions have alternated between gains and declines, suggesting uneven investor conviction around updates like today’s Form 10-Q filing and operational progress commentary.
Market Pulse Summary
This announcement highlights filing of the first quarter 2026 Form 10-Q alongside continued advancement of lead compound LB-100 and integration of the Liora proton therapy platform. Recent history shows ongoing activity in ovarian cancer trials and expansion of the LIGHT System in Europe. Investors may focus on upcoming clinical readouts, execution on Liora development plans, and any updates within future SEC filings that further detail cash resources, trial timelines, and commercialization strategy for both drug and med-tech programs.
Key Terms
form 10-q regulatory
proton therapy medical
immune checkpoint blockade (icb) medical
ovarian clear cell carcinoma (occc) medical
pp2a medical
ppp2r1a medical
forward-looking statements regulatory
AI-generated analysis. Not financial advice.
BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (“SEC”) for the first quarter ended March 31, 2026. The report is available on the Company’s website, www.lixte.com, and on the SEC’s website, www.sec.gov.
“We are making progress in advancing our lead compound, LB-100, which has consistently shown synergy with today’s chemotherapy and immunotherapy approaches for the treatment of cancer,” said Geordan Pursglove, LIXTE’s Chairman and Chief Executive Officer. “Following a recent study confirming the favorable safety profile of LB-100 in combination with GSK’s dostarlimab, we have expanded our ovarian cancer trial and continue to enroll additional patients.
“The continued growth of our recently acquired Liora Technologies Europe subsidiary (“Liora) further strengthens our ability to accelerate innovative cancer therapies, including the treatment of tumors using proton therapy through Liora’s LIGHT System,” added Pursglove. “We continue to evaluate opportunities to expand strategically and look forward to further growing our team through the pursuit of complementary oncology assets that enhance our pipeline and accelerate the development of new and effective treatments. I am proud of our team’s dedication to delivering meaningful innovation for patients, and believe that continued progress will drive improved outcomes and long-term value for our shareholders.”
Recent Operational Highlights
- Advanced integration and strategic development initiatives at Liora Technologies Europe during the first quarter of 2026, supporting the continued expansion of the LIGHT System platform and strengthening the Company’s position in innovative proton therapy solutions.
- Sponsored inaugural Good Health: Mind, Body & Soul Summit, bringing together leaders in health, culture, science, and community to advance health equity for Black men and families. The Summit aligns with LIXTE’s commitment to advancing cancer care through LB-100, and its Liora research subsidiary.
- Presented favorable preliminary results for a clinical trial testing the combination of Lixte’s proprietary compound LB-100 in combination with dostarlimab at the 2026 Conference of the Society of Gynecological Cancer in Puerto Rico. The trial is based on the observation by the lead clinical investigator, Amir Jazaeri MD, Professor of Gynecologic Oncology at The University of Texas MD Anderson Cancer Center, that a genetically acquired reduction in PP2A activity may increase responsiveness to immune checkpoint blockade (ICB) in Ovarian Clear Cell Carcinoma (OCCC), particularly in tumors harboring somatic PPP2R1A mutations resulting in loss of protein phosphatase 2A (PP2A) function.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
# # #
